StockMacro
Company, fund or insider

Help

Menu

Solventum

$84.50 +11% in 6 monthsMarket cap $14.3B

SOLV on XNYS, Health Care, Solventum Corporation, job postings

Measures activity, not value. Not investment advice.

Quarterly revenue fell 7.0% to $1.9B and 12-month profit dropped 90% to $156M.

  • BadFree cash flow was $0 over 12 months; net debt $4.6B

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and infection prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
20,000
Website
solventum.com
Listed
NYSE, US
Last results
5 Nov 2026
Next results
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.9B, net loss $12.0M.
Quarter to 31 Mar 2023: revenue $2.0B, net income $293.0MQuarter to 31 Mar 2023: revenue $2.0B, net income $293.0MQuarter to 30 Jun 2023: revenue $2.1B, net income $321.0MQuarter to 30 Jun 2023: revenue $2.1B, net income $321.0MQuarter to 30 Sep 2023: revenue $2.1B, net income $460.0MQuarter to 30 Sep 2023: revenue $2.1B, net income $460.0MQuarter to 31 Dec 2023: revenue $2.0B, net income $272.0MQuarter to 31 Dec 2023: revenue $2.0B, net income $272.0MQuarter to 31 Mar 2024: revenue $2.0B, net income $237.0MQuarter to 31 Mar 2024: revenue $2.0B, net income $237.0MQuarter to 30 Jun 2024: revenue $2.1B, net income $89.0MQuarter to 30 Jun 2024: revenue $2.1B, net income $89.0MQuarter to 30 Sep 2024: revenue $2.1B, net income $122.0MQuarter to 30 Sep 2024: revenue $2.1B, net income $122.0MQuarter to 31 Dec 2024: revenue $2.1B, net income $31.0MQuarter to 31 Dec 2024: revenue $2.1B, net income $31.0MQuarter to 31 Mar 2025: revenue $2.1B, net income $137.0MQuarter to 31 Mar 2025: revenue $2.1B, net income $137.0MQuarter to 30 Jun 2025: revenue $2.2B, net income $90.0MQuarter to 30 Jun 2025: revenue $2.2B, net income $90.0MQuarter to 30 Sep 2025: revenue $2.1B, net income $1.3BQuarter to 30 Sep 2025: revenue $2.1B, net income $1.3BQuarter to 31 Dec 2025: revenue $2.0B, net income $63.0MQuarter to 31 Dec 2025: revenue $2.0B, net income $63.0MQuarter to 31 Mar 2026: revenue $2.0B, net income $13.0MQuarter to 31 Mar 2026: revenue $2.0B, net income $13.0MQuarter to 30 Jun 2026: revenue $2.2B, net income $92.0MQuarter to 30 Jun 2026: revenue $2.2B, net income $92.0MQuarter to 30 Sep 2026: revenue $1.9B, net income -$12.0MQuarter to 30 Sep 2026: revenue $1.9B, net income -$12.0M
31 Mar 2023RevenueNet incomeNet losstallest bar $2.2B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.9B-$12.0M
30 Jun 2026$2.2B$92.0M
31 Mar 2026$2.0B$13.0M
31 Dec 2025$2.0B$63.0M
30 Sep 2025$2.1B$1.3B
30 Jun 2025$2.2B$90.0M
31 Mar 2025$2.1B$137.0M
31 Dec 2024$2.1B$31.0M
30 Sep 2024$2.1B$122.0M
30 Jun 2024$2.1B$89.0M
31 Mar 2024$2.0B$237.0M
31 Dec 2023$2.0B$272.0M
30 Sep 2023$2.1B$460.0M
30 Jun 2023$2.1B$321.0M
31 Mar 2023$2.0B$293.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $8.2B $8.4B
Revenue growthRevenue of the last 12 months compared with the 12 months before. -2.8% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $156.0M $1.5B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.88 $8.69
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 54.8% 54.1% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 5.6% 26.1% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 1.9% 18.1% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 3.2% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $0 $50.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $451.0M $1.6B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $5.1B $5.1B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $4.6B $3.5B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 1.1 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $28.31
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 91.9 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.8 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.3 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.0 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
SolventumSOLV (this company) $14.3B91.91.8-2.8%1.9%
GlaukosGKOS $14.0Bloss20.3+47%-24.6%
Baxter InternationalBAX $13.1Bloss1.1+6.0%-6.0%
PenumbraPEN $12.6B80.18.1+17%10.1%
InsuletPODD $9.2B21.52.9+26%13.4%
Globus MedicalGMED $8.9B16.12.9+13%17.8%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-7.0%

$1.9B vs $2.1B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-18%

$80.0M vs $97.0M (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.3%

888 13F filers vs 860

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

75%

127.2M shares held by 13F filers (30 Sep 2026) of 169.7M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.0%

5.0M shares sold short (30 Oct 2026) of 169.7M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.6

5.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.9%

5.0M shares sold short in the report before, 5.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

44%

44% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$25K

the 12 months before: $0

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$1.0M

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.7×

11 articles in the last 7 days; its usual week has 3.

Price $84.50 on 20 Nov 2026, +6.3% over 12 months (12-month range $62.49 to $92.44)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $100K in the last 12 months (the 12 months before: -$646.4M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 16 published in the last 12 months, +78% on the 12 months before.
Revenue per quarter. Revenue $1.9B in the latest quarter, -7.0% on a year earlier.
Capital spending per quarter. Capital spending $80.0M in the latest quarter, -18% on a year earlier.
Institutional holders (13F filers). 888 13F filers reported holding it in the latest 13F quarter, +8.6% on a year earlier.
Federal obligations. Federal obligations: $85K published in the last 12 months, -53% on the 12 months before.
Lobbying spend. Lobbying spend: $1.0M published in the last 12 months, +37% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
20 Jul 20268-K and other filingsDirector or officer change
16 Jun 2026Sharp changeShort interest spike: short interest spike, 7.6M vs usual 4.0M (2026-05-29); 1.7x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 7.9M vs usual 4.0M (2026-05-15); 1.7x the same period a year earlier
27 May 20268-K and other filingsDirector or officer change
12 May 2026Sharp changeShort interest spike: short interest spike, 6.5M vs usual 4.0M (2026-04-30); 1.6x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 6.4M vs usual 4.0M (2026-04-15); 1.5x the same period a year earlier
24 Mar 20268-K and other filingsDirector or officer change
24 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Feb 2026Lobbying filingnew lobbying registration (MONUMENT ADVOCACY)
14 Jan 2026Lobbying filinglobbying engagement terminated (HORIZON GOVERNMENT AFFAIRS)
21 Oct 20258-K and other filingsDirector or officer change
21 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Oct 2025Lobbying filingnew lobbying registration (HORIZON GOVERNMENT AFFAIRS)
2 Sep 20258-K and other filingsCompleted an acquisition or asset sale
21 Apr 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MED, SCI (2025-03-31)
15 Apr 2025Lobbying filingnew lobbying registration (TIBER CREEK GROUP)
19 Mar 2025Lobbying filingnew lobbying registration (NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC))
21 Jan 2025Sharp changeLobbying on a new issue: lobbying on a new issue: DEF, TRD, VET (2024-12-31)
5 Nov 20248-K and other filingsDirector or officer change
5 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 May 20248-K and other filingsDirector or officer change
16 Apr 20248-K and other filingsDirector or officer change
4 Apr 20248-K and other filingsDirector or officer change
4 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Apr 2023Lobbying filinglobbying engagement terminated (ARNOLD & PORTER KAYE SCHOLER LLP)
18 Apr 2022Lobbying filinglobbying engagement terminated (KING & SPALDING LLP)
Insider net buying (open market)
Month from 1 Aug 2025: -$646.4M published
Month from 1 Mar 2026: $100K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Jul 2025: 5 published
Quarter from 1 Oct 2025: 4 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Jul 2026: 8 published
Quarter from 1 Oct 2026: 7 published
Revenue per quarter
Quarter ended 31 Mar 2023: $2.0B; public on 11 May 2024
Quarter ended 30 Jun 2023: $2.1B; public on 10 Aug 2024
Quarter ended 30 Sep 2023: $2.1B; public on 9 Nov 2024
Quarter ended 31 Dec 2023: $2.0B; public on 1 Mar 2025
Quarter ended 31 Mar 2024: $2.0B, +0.2% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $2.1B, +0.2% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $2.1B, +0.4% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $2.1B, +1.9% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $2.1B, +2.7% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $2.2B, +3.8% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $2.1B, +0.7% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $2.0B, -3.7% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $2.0B, -3.0% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $2.2B, +2.2% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $1.9B, -7.0% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2023: $65.0M; public on 11 May 2024
Quarter ended 30 Jun 2023: $71.0M; public on 10 Aug 2024
Quarter ended 30 Sep 2023: $66.0M; public on 9 Nov 2024
Quarter ended 31 Dec 2023: $88.0M; public on 1 Mar 2025
Quarter ended 31 Mar 2024: $102.0M, +57% on a year earlier; public on 11 May 2024
Quarter ended 30 Jun 2024: $58.0M, -18% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $93.0M, +41% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $127.0M, +44% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $109.0M, +6.9% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $110.0M, +90% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $97.0M, +4.3% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $63.0M, -50% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $84.0M, -23% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $83.0M, -25% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $80.0M, -18% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Mar 2024 report: 59; public on 15 May 2024
30 Jun 2024 report: 844; public on 14 Aug 2024
30 Sep 2024 report: 870; public on 14 Nov 2024
31 Dec 2024 report: 886; public on 14 Feb 2025
31 Mar 2025 report: 863; public on 15 May 2025
30 Jun 2025 report: 834; public on 14 Aug 2025
30 Sep 2025 report: 818; public on 14 Nov 2025
31 Dec 2025 report: 892; public on 17 Feb 2026
31 Mar 2026 report: 857; public on 15 May 2026
30 Jun 2026 report: 860; public on 14 Aug 2026
30 Sep 2026 report: 888; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2024: $14K published
Month from 1 Jan 2025: $27K published
Month from 1 Feb 2025: $30K published
Month from 1 Apr 2025: $18K published
Month from 1 May 2025: $0 published
Month from 1 Jul 2025: $82K published
Month from 1 Aug 2025: $0 published
Month from 1 Sep 2025: $349 published
Month from 1 Oct 2025: $10K published
Month from 1 Feb 2026: $234 published
Month from 1 Mar 2026: $0 published
Month from 1 Jun 2026: $13K published
Month from 1 Sep 2026: $70K published
Month from 1 Oct 2026: $941 published
Lobbying spend
Quarter from 1 Jan 2022: $100K published
Quarter from 1 Apr 2022: $70K published
Quarter from 1 Jul 2022: $70K published
Quarter from 1 Oct 2022: $100K published
Quarter from 1 Jan 2023: $70K published
Quarter from 1 Apr 2023: $10K published
Quarter from 1 Jul 2023: $10K published
Quarter from 1 Oct 2023: $50K published
Quarter from 1 Jan 2024: $50K published
Quarter from 1 Apr 2024: $100K published
Quarter from 1 Jul 2024: $10K published
Quarter from 1 Oct 2024: $50K published
Quarter from 1 Jan 2025: $90K published
Quarter from 1 Apr 2025: $330K published
Quarter from 1 Jul 2025: $150K published
Quarter from 1 Oct 2025: $190K published
Quarter from 1 Jan 2026: $310K published
Quarter from 1 Apr 2026: $300K published
Quarter from 1 Jul 2026: $250K published
Quarter from 1 Oct 2026: $180K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $100K (11 Mar 2026), too little history to compare.
  • Short interest spike: had 7.9M shares sold short in the 15 May 2026 report, 1.7× the same report last year Public on 28 May 2026.
  • Insider net buying (open market): Insiders bought a net $100K in the last 12 months (the 12 months before: -$646.4M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 16 published in the last 12 months, +78% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 2 insider trades

No trades in the last 90 days; the latest was filed 11 Mar 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
11 Mar 2026Amy McBride WendellDirectorBuy1,475$68.03$100KForm 4
18 Aug 20253M Co10% ownerSell8,800,000$73.45$646.4MForm 4

888 institutions reported shares at the end of Q3 2026, 75% of the shares outstanding; 84 opened a position, 65 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Independent Franchise Partners LLP15.7M9.23%$1.4B-498K-3.1%
BlackRock, Inc.9.6M5.63%$842.4M-205K-2.1%
Vanguard Capital Management LLC9.5M5.58%$835.4M-148K-1.5%
Trian Fund Management, L.P.8.2M4.85%$726.1MNo change
Davis Selected Advisers6.4M3.78%$565.4M+107K+1.7%
Vanguard Portfolio Management LLC6.2M3.65%$546.7M-127K-2.0%
State Street Corp5.6M3.31%$495.0M-24K-0.4%
Geode Capital Management, LLC5.0M2.92%$436.3M+46K+0.9%
Boston Partners3.6M2.11%$315.4M-460K-11%
Invesco Ltd.3.2M1.89%$282.1M-109K-3.3%

Company events

All 12 company events

In 12 months: 3 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Jul 2026Director or officer change8-K
27 May 2026Director or officer change8-K
24 Mar 2026Director or officer change8-K
21 Oct 2025Director or officer change8-K
2 Sep 2025Completed an acquisition or asset sale8-K
25 Jun 2025Signed a major agreement8-K
27 Feb 2025Signed a major agreement8-K
5 Nov 2024Director or officer change8-K

Reported lobbying spend: $180K in Q3 2026, $250K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jan 2026NewMonument Advocacyfor Solventum Health Information Systems, Inc.Implementation of one big beautiful bill; Medicare quality programs (hospitals, doctors, Medicare Advantage); Medicaid quality programs and STARS ratingsHealth issuesFiling
31 Dec 2025EndedHorizon Government Affairsfor Solventum Health Information Systems, IncImplementation of one big beautiful bill; Medicare quality programs (hospitals, doctors, Medicare Advantage); Medicaid quality programs and STARS ratingsHealth issuesFiling
1 Sep 2025NewHorizon Government Affairsfor Solventum Health Information Systems, IncImplementation of one big beautiful bill. Medicare quality programs (hospitals, doctors, Medicare Advantage).Health issuesFiling
11 Mar 2025NewTiber Creek Groupfor Solventum CorporationIssues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.Health issues, Medicare/Medicaid, TradeFiling
1 Feb 2025NewNavigators Global LLC (Formerly DC Navigators, LLC)for SolventumIssues related to trade policy. Issues related to healthcare policy. Issues related to medical, dental, and health information systems research and development.Trade, MED, Health issues, Medicare/Medicaid, Science/technologyFiling
31 Mar 2023EndedArnold & Porter Kaye Scholer LLPfor Acera SurgicalNot statedFiling
31 Dec 2022EndedKing & Spalding LLPfor Acera Surgical, Inc.Not statedFiling
20 Sep 2021NewKing & Spalding LLPfor Acera Surgical, Inc.Advocacy on synthetic skin substitute issuesMedicare/MedicaidFiling

The 5 newest of 224 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 20 Jul 2026Filings record

    Director or officer change

  2. 10 Jun 2026Short interest and volume change

    had 7.6M shares sold short in the 29 May 2026 report, 1.7× the same report last year.

    Same report last year: 4.5M; its normal report is 4.0M.

    See the evidence
    This period
    7.6M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    4.0M
    Typical spread (median absolute deviation)
    365K
    How far from its usual level
    +6.6
    Same report last year
    4.5M
    History used
    774 days
    2025-05-30: 4.5M2025-06-13: 4.2M2025-06-30: 4.4M2025-07-15: 3.9M2025-07-31: 3.8M2025-08-15: 3.9M2025-08-29: 4.3M2025-09-15: 4.0M2025-09-30: 3.9M2025-10-15: 4.4M2025-10-31: 4.9M2025-11-14: 4.1M2025-11-28: 3.7M2025-12-15: 3.5M2025-12-31: 4.0M2026-01-15: 3.7M2026-01-30: 3.7M2026-02-13: 3.5M2026-02-27: 3.5M2026-03-13: 4.0M2026-03-31: 5.4M2026-04-15: 6.4M2026-04-30: 6.5M2026-05-15: 7.9M2026-05-29: 7.6M
    the 29 May 2026 report24 earlier reportsnormal: 4.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 28 May 2026Short interest and volume change

    had 7.9M shares sold short in the 15 May 2026 report, 1.7× the same report last year.

    Same report last year: 4.6M; its normal report is 4.0M.

    See the evidence
    This period
    7.9M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    4.0M
    Typical spread (median absolute deviation)
    365K
    How far from its usual level
    +7.1
    Same report last year
    4.6M
    History used
    760 days
    2025-05-15: 4.6M2025-05-30: 4.5M2025-06-13: 4.2M2025-06-30: 4.4M2025-07-15: 3.9M2025-07-31: 3.8M2025-08-15: 3.9M2025-08-29: 4.3M2025-09-15: 4.0M2025-09-30: 3.9M2025-10-15: 4.4M2025-10-31: 4.9M2025-11-14: 4.1M2025-11-28: 3.7M2025-12-15: 3.5M2025-12-31: 4.0M2026-01-15: 3.7M2026-01-30: 3.7M2026-02-13: 3.5M2026-02-27: 3.5M2026-03-13: 4.0M2026-03-31: 5.4M2026-04-15: 6.4M2026-04-30: 6.5M2026-05-15: 7.9M
    the 15 May 2026 report24 earlier reportsnormal: 4.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 27 May 2026Filings record

    Director or officer change

  5. 12 May 2026Short interest and volume change

    had 6.5M shares sold short in the 30 Apr 2026 report, 1.6× the same report last year.

    Same report last year: 4.1M; its normal report is 4.0M.

    See the evidence
    This period
    6.5M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    4.0M
    Typical spread (median absolute deviation)
    355K
    How far from its usual level
    +4.7
    Same report last year
    4.1M
    History used
    745 days
    2025-04-30: 4.1M2025-05-15: 4.6M2025-05-30: 4.5M2025-06-13: 4.2M2025-06-30: 4.4M2025-07-15: 3.9M2025-07-31: 3.8M2025-08-15: 3.9M2025-08-29: 4.3M2025-09-15: 4.0M2025-09-30: 3.9M2025-10-15: 4.4M2025-10-31: 4.9M2025-11-14: 4.1M2025-11-28: 3.7M2025-12-15: 3.5M2025-12-31: 4.0M2026-01-15: 3.7M2026-01-30: 3.7M2026-02-13: 3.5M2026-02-27: 3.5M2026-03-13: 4.0M2026-03-31: 5.4M2026-04-15: 6.4M2026-04-30: 6.5M
    the 30 Apr 2026 report24 earlier reportsnormal: 4.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 25 Apr 2026Short interest and volume change

    had 6.4M shares sold short in the 15 Apr 2026 report, 1.5× the same report last year.

    Same report last year: 4.4M; its normal report is 4.0M.

    See the evidence
    This period
    6.4M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    4.0M
    Typical spread (median absolute deviation)
    351K
    How far from its usual level
    +4.5
    Same report last year
    4.4M
    History used
    730 days
    2025-04-15: 4.4M2025-04-30: 4.1M2025-05-15: 4.6M2025-05-30: 4.5M2025-06-13: 4.2M2025-06-30: 4.4M2025-07-15: 3.9M2025-07-31: 3.8M2025-08-15: 3.9M2025-08-29: 4.3M2025-09-15: 4.0M2025-09-30: 3.9M2025-10-15: 4.4M2025-10-31: 4.9M2025-11-14: 4.1M2025-11-28: 3.7M2025-12-15: 3.5M2025-12-31: 4.0M2026-01-15: 3.7M2026-01-30: 3.7M2026-02-13: 3.5M2026-02-27: 3.5M2026-03-13: 4.0M2026-03-31: 5.4M2026-04-15: 6.4M
    the 15 Apr 2026 report24 earlier reportsnormal: 4.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 24 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 24 Mar 2026Filings record

    Director or officer change

  9. 12 Mar 2026Insiders record

    Wendell Amy McBride (director) bought 1,475 shares of SOLV ($100,344) (dated 11 Mar 2026)

  10. 13 Feb 2026Lobbying record

    SOLVENTUM HEALTH INFORMATION SYSTEMS, INC.: new lobbying registration (MONUMENT ADVOCACY) (dated 1 Jan 2026)

  11. 14 Jan 2026Lobbying record

    SOLVENTUM HEALTH INFORMATION SYSTEMS, INC: lobbying engagement terminated (HORIZON GOVERNMENT AFFAIRS) (dated 31 Dec 2025)

  12. 21 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 21 Oct 2025Filings record

    Director or officer change

  14. 17 Oct 2025Lobbying record

    SOLVENTUM HEALTH INFORMATION SYSTEMS, INC: new lobbying registration (HORIZON GOVERNMENT AFFAIRS) (dated 1 Sep 2025)

  15. 2 Sep 2025Filings record

    Completed an acquisition or asset sale

  16. 21 Apr 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MED', 'SCI']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6139646
  17. 15 Apr 2025Lobbying record

    SOLVENTUM CORPORATION: new lobbying registration (TIBER CREEK GROUP) (dated 11 Mar 2025)

  18. 19 Mar 2025Lobbying record

    SOLVENTUM: new lobbying registration (NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC)) (dated 1 Feb 2025)

  19. 21 Jan 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['DEF', 'TRD', 'VET']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6274378
  20. 5 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 5 Nov 2024Filings record

    Director or officer change

  22. 14 Aug 2024Institutional holdings record

    STATE STREET CORP opened a $313.0M position (2024Q2 13F)

  23. 13 Aug 2024Institutional holdings record

    VANGUARD GROUP INC opened a $862.0M position (2024Q2 13F)

  24. 13 Aug 2024Institutional holdings record

    BlackRock Inc. opened a $584.0M position (2024Q2 13F)

  25. 7 Aug 2024Institutional holdings record

    Davis Selected Advisers opened a $273.0M position (2024Q2 13F)

  26. 17 May 2024Filings record

    Director or officer change

  27. 16 Apr 2024Filings record

    Director or officer change

  28. 4 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 4 Apr 2024Filings record

    Director or officer change

  30. 14 Apr 2023Lobbying record

    ACERA SURGICAL: lobbying engagement terminated (ARNOLD & PORTER KAYE SCHOLER LLP) (dated 31 Mar 2023)

  31. 18 Apr 2022Lobbying record

    ACERA SURGICAL, INC.: lobbying engagement terminated (KING & SPALDING LLP) (dated 31 Dec 2022)

  32. 14 Oct 2021Lobbying record

    ACERA SURGICAL, INC.: new lobbying registration (KING & SPALDING LLP) (dated 20 Sep 2021)

  33. 8 Oct 2019Lobbying record

    KCI USA, INC.: lobbying engagement terminated (POLSINELLI PC) (dated 30 Sep 2019)

  34. 18 Apr 2019Lobbying record

    ACERA SURGICAL: new lobbying registration (ARNOLD & PORTER KAYE SCHOLER LLP) (dated 25 Mar 2019)

  35. 19 May 2017Lobbying record

    KCI USA, INC.: new lobbying registration (POLSINELLI PC) (dated 15 May 2017)

  36. 20 Apr 2017Lobbying record

    SOLVENTUM CORPORATION: new lobbying registration (in-house) (dated 1 Mar 2017)

  37. 14 Apr 2017Lobbying record

    KCI USA, INC.: lobbying engagement terminated (HOLLAND & KNIGHT LLP) (dated 31 Mar 2017)

  38. 13 Oct 2015Lobbying record

    KCI USA, INC.: new lobbying registration (HOLLAND & KNIGHT LLP) (dated 23 Sep 2015)

  39. 20 Jul 2012Lobbying record

    KCI USA INC.: lobbying engagement terminated (BALLARD SPAHR LLP) (dated 15 Jun 2012)

  40. 20 Jul 2012Lobbying record

    KCI USA, INC.: lobbying engagement terminated (in-house) (dated 30 Jun 2012)

Showing the newest 40 of 42 entries; narrow the window or the kind of data to see older ones.

Not listed: 32 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001964738
Ticker
SOLV
Domain
solventum.com
Employer name
3m healthcare latam apac export, 3M Healthcare US Opco LLC, 3M Healthcare US Opco LLC (a subsidiary of 3M Company), solventum health information systems and 3 more (7 unverified)
Fein
52-1322009, 92-2596326, 92-2623933 (3 unverified)
Hq location
MN|EAGAN|55121 (1 unverified)
Lobbying client
acera surgical, solventum, solventum health information systems
Name
3M Healthcare Canada Company Limited, 3M Health Care Co, 3M Healthcare EMEA Export Limited, 3M Healthcare LATAM/APAC Export Corporation and 104 more
Uei
NYZ3A8USQ3X9
Wikidata
Q124795355
Wikipedia
Solventum
  • DOL H-1B labor condition applications and PERM certifications102 data points26 Aug 2024 to 7 Sep 2026
  • Federal lobbying disclosures (LDA)18 records, 145 data points5 Sep 2011 to 30 Sep 2026
  • SEC Form 13F institutional holdings4 records, 99 data points31 Mar 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)40 records4 Apr 2024 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)256 data points31 Dec 2021 to 31 Oct 2026
  • SEC Form 4 insider transactions2 records, 8 data points18 Aug 2025 to 11 Mar 2026
  • FINRA short interest (twice monthly)186 data points15 Apr 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1330 data points1 Apr 2024 to 20 Nov 2026
  • USASpending.gov federal awards66 data points13 Nov 2024 to 23 Sep 2026
  • Wikipedia pageviews1002 data points23 Feb 2024 to 20 Nov 2026